A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report: Clinical Oncology/Epidemiology

A prospective, randomised controlled trial of surgery, surgery with adjuvant radiotherapy and surgery with adjuvant chemotherapy (5-fluorouracil, adriamycin and mitomycin C) in operable gastric cancer is described. Four hundred and thirty-six patients were randomly allocated to one of three treatmen...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1989-11, Vol.60 (5), p.739-744
Main Authors: Allum, WH, Hallissey, MT, Ward, LC, Hockey, MS
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Cancer Research
clinical-oncology-epidemiology
Drug Resistance
Epidemiology
Molecular Medicine
Oncology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 744
container_issue 5
container_start_page 739
container_title British journal of cancer
container_volume 60
creator Allum, WH
Hallissey, MT
Ward, LC
Hockey, MS
description A prospective, randomised controlled trial of surgery, surgery with adjuvant radiotherapy and surgery with adjuvant chemotherapy (5-fluorouracil, adriamycin and mitomycin C) in operable gastric cancer is described. Four hundred and thirty-six patients were randomly allocated to one of three treatment groups. With 12 months' minimum follow-up, 334 patients have died, 292 from recurrent cancer. The median survival for all patients was 15 months. Neither form of adjuvant therapy provides any survival advantage. Surgery remains the principal treatment for operable gastric cancer. Care should be taken to standardise surgical treatment and any adjuvant treatments must be compared within the confines of controlled, randomised trials.
doi_str_mv 10.1038/bjc.1989.350
format article
fullrecord <record><control><sourceid>springer</sourceid><recordid>TN_cdi_springer_journals_10_1038_bjc_1989_350</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1038_bjc_1989_350</sourcerecordid><originalsourceid>FETCH-springer_journals_10_1038_bjc_1989_3503</originalsourceid><addsrcrecordid>eNqVj0FqwzAQRUVpoG6bXQ8wB4idkU2w3V0pLT1A90KRJomMLYmREuiyN68Cpfuuhs9_f-AJ8SSxkdgN2_1kGjkOY9Pt8EZUcte1tRza_lZUiNjXOLZ4J-5Tmkoccegr8f0CJvjMYZ7JbiBySJFMdhfaAGtvw-ISWcjs9AzhANpO54v2GcyJlpBPxDp-QeACW_eXnQemVP7o_Uxw1KnsDRjtDfFzaTOxWwoSA-dHsTroOdH69z6I-v3t8_WjTpGdPxKrKZzZl0pJVFdPVTzV1VMVz-6__A9v1152</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report: Clinical Oncology/Epidemiology</title><source>PubMed Central</source><creator>Allum, WH ; Hallissey, MT ; Ward, LC ; Hockey, MS</creator><creatorcontrib>Allum, WH ; Hallissey, MT ; Ward, LC ; Hockey, MS</creatorcontrib><description>A prospective, randomised controlled trial of surgery, surgery with adjuvant radiotherapy and surgery with adjuvant chemotherapy (5-fluorouracil, adriamycin and mitomycin C) in operable gastric cancer is described. Four hundred and thirty-six patients were randomly allocated to one of three treatment groups. With 12 months' minimum follow-up, 334 patients have died, 292 from recurrent cancer. The median survival for all patients was 15 months. Neither form of adjuvant therapy provides any survival advantage. Surgery remains the principal treatment for operable gastric cancer. Care should be taken to standardise surgical treatment and any adjuvant treatments must be compared within the confines of controlled, randomised trials.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1989.350</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; clinical-oncology-epidemiology ; Drug Resistance ; Epidemiology ; Molecular Medicine ; Oncology</subject><ispartof>British journal of cancer, 1989-11, Vol.60 (5), p.739-744</ispartof><rights>Cancer Research Campaign 1989</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Allum, WH</creatorcontrib><creatorcontrib>Hallissey, MT</creatorcontrib><creatorcontrib>Ward, LC</creatorcontrib><creatorcontrib>Hockey, MS</creatorcontrib><title>A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report: Clinical Oncology/Epidemiology</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>A prospective, randomised controlled trial of surgery, surgery with adjuvant radiotherapy and surgery with adjuvant chemotherapy (5-fluorouracil, adriamycin and mitomycin C) in operable gastric cancer is described. Four hundred and thirty-six patients were randomly allocated to one of three treatment groups. With 12 months' minimum follow-up, 334 patients have died, 292 from recurrent cancer. The median survival for all patients was 15 months. Neither form of adjuvant therapy provides any survival advantage. Surgery remains the principal treatment for operable gastric cancer. Care should be taken to standardise surgical treatment and any adjuvant treatments must be compared within the confines of controlled, randomised trials.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>clinical-oncology-epidemiology</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVj0FqwzAQRUVpoG6bXQ8wB4idkU2w3V0pLT1A90KRJomMLYmREuiyN68Cpfuuhs9_f-AJ8SSxkdgN2_1kGjkOY9Pt8EZUcte1tRza_lZUiNjXOLZ4J-5Tmkoccegr8f0CJvjMYZ7JbiBySJFMdhfaAGtvw-ISWcjs9AzhANpO54v2GcyJlpBPxDp-QeACW_eXnQemVP7o_Uxw1KnsDRjtDfFzaTOxWwoSA-dHsTroOdH69z6I-v3t8_WjTpGdPxKrKZzZl0pJVFdPVTzV1VMVz-6__A9v1152</recordid><startdate>19891101</startdate><enddate>19891101</enddate><creator>Allum, WH</creator><creator>Hallissey, MT</creator><creator>Ward, LC</creator><creator>Hockey, MS</creator><general>Nature Publishing Group UK</general><scope/></search><sort><creationdate>19891101</creationdate><title>A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report</title><author>Allum, WH ; Hallissey, MT ; Ward, LC ; Hockey, MS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-springer_journals_10_1038_bjc_1989_3503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>clinical-oncology-epidemiology</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Allum, WH</creatorcontrib><creatorcontrib>Hallissey, MT</creatorcontrib><creatorcontrib>Ward, LC</creatorcontrib><creatorcontrib>Hockey, MS</creatorcontrib><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Allum, WH</au><au>Hallissey, MT</au><au>Ward, LC</au><au>Hockey, MS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report: Clinical Oncology/Epidemiology</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><date>1989-11-01</date><risdate>1989</risdate><volume>60</volume><issue>5</issue><spage>739</spage><epage>744</epage><pages>739-744</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>A prospective, randomised controlled trial of surgery, surgery with adjuvant radiotherapy and surgery with adjuvant chemotherapy (5-fluorouracil, adriamycin and mitomycin C) in operable gastric cancer is described. Four hundred and thirty-six patients were randomly allocated to one of three treatment groups. With 12 months' minimum follow-up, 334 patients have died, 292 from recurrent cancer. The median survival for all patients was 15 months. Neither form of adjuvant therapy provides any survival advantage. Surgery remains the principal treatment for operable gastric cancer. Care should be taken to standardise surgical treatment and any adjuvant treatments must be compared within the confines of controlled, randomised trials.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><doi>10.1038/bjc.1989.350</doi></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 1989-11, Vol.60 (5), p.739-744
issn 0007-0920
1532-1827
language eng
recordid cdi_springer_journals_10_1038_bjc_1989_350
source PubMed Central
subjects Biomedical and Life Sciences
Biomedicine
Cancer Research
clinical-oncology-epidemiology
Drug Resistance
Epidemiology
Molecular Medicine
Oncology
title A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report: Clinical Oncology/Epidemiology
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A49%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-springer&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20controlled,%20prospective,%20randomised%20trial%20of%20adjuvant%20chemotherapy%20or%20radiotherapy%20in%20resectable%20gastric%20cancer:%20interim%20report:%20Clinical%20Oncology/Epidemiology&rft.jtitle=British%20journal%20of%20cancer&rft.au=Allum,%20WH&rft.date=1989-11-01&rft.volume=60&rft.issue=5&rft.spage=739&rft.epage=744&rft.pages=739-744&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/bjc.1989.350&rft_dat=%3Cspringer%3E10_1038_bjc_1989_350%3C/springer%3E%3Cgrp_id%3Ecdi_FETCH-springer_journals_10_1038_bjc_1989_3503%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true